Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine) in patients with moderate-to-severe Alzheimer’s disease (AD).

The CONTACT study will assess as primary endpoints the potential benefits of adding dimebon to ongoing treatment with donepezil HCI tablets, the leading AD medication worldwide, on neuropsychiatric symptoms and activities of daily living. The CONSTELLATION study will evaluate as primary endpoints the effects of adding dimebon to memantine HCI, another standard of care, on cognition, memory and activities of daily living.

“Alzheimer’s disease is a growing global epidemic with an unmet clinical need. Many patients with moderate-to-severe Alzheimer’s disease experience behavioral and neuropsychiatric symptoms, which are among the leading causes of placement in care facilities for these patients,” said Pierre N. Tariot, MD, director of the Memory Disorders Center at the Banner Alzheimer’s Institute and study investigator. “These studies are intended to evaluate the potential added benefits of dimebon in combination with current standards of Alzheimer’s care.”

In preclinical studies, dimebon has been shown to protect brain cells from damage and enhance brain cell survival, potentially by stabilizing and improving mitochondrial function. The dimebon mechanism is distinct from currently available AD medications.

“Pfizer and Medivation are committed to developing dimebon as a treatment that may meaningfully improve the lives of patients across the full spectrum of Alzheimer’s disease severity,” said Lynn Seely, M.D., chief medical officer for Medivation. “The initiation of the CONTACT and CONSTELLATION studies is an important milestone in the broad clinical development of dimebon.”

These studies are part of a comprehensive Phase 3 clinical development program, currently consisting of seven trials, to assess the safety and efficacy of dimebon across all stages of Alzheimer’s disease, as monotherapy and in combination with currently available Alzheimer’s treatments, and in Huntington disease.


Medivation and Pfizer


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers identify neurons in a small brain region that delay feeding initiation